BioSpace News Archive

Curis, Inc. last night presented clinical data from its TakeAim Leukemia Study at the 2023 ASH Conference.

Zafrens, a multi-modality drug discovery company, announced the close of $23 million in financing led by Prime Movers Lab with participation from BlueYard Capital, KOFA Healthcare, Global Brains, FoundersX Ventures, Alix Ventures, Possible Ventures, Iaso Ventures, Hawktail, and other investors.

Synchron, the endovascular brain-computer interface company developing technology designed to restore functionality in patients with motor impairment, announced the appointment of Andy Rasdal to its Board of Directors.

New Thermo Scientific KingFisher Apex Dx system and Applied Biosystems MagMAX Dx Isolation Kit improve preanalytical workflows for clinical laboratories.

Tharimmune, Inc. (Nasdaq:THAR) (“Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions announces positive phase 1 data with TH104, a proprietary transmucosal buccal film which easily adheres to the inside of the mouth.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented in an oral presentation at the 65th Annual American Society of Hematology Meeting & Exposition (ASH).

Mustang Bio, Inc. today announced updated encouraging safety and efficacy data from Mustang’s multicenter Phase 1/2 clinical trial of MB-106, a CD20-targeted, 3rd-generation autologous CAR T-cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic lymphocytic leukemia (“CLL”).

Fractyl Health presented preclinical findings from its Rejuva® gene therapy platform at the World Congress Insulin Resistance Diabetes and Cardiovascular Disease 2023 Annual Meeting.

Electra Therapeutics, Inc. announced the presentation of the first clinical data for ELA026, the company’s lead candidate in development for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening inflammatory disease.

CalciMedica Inc. today announced that its collaborator, St. Jude Children’s Research Hospital (SJCRH), presented data from the initial cohort of the Phase 1/2 CRSPA study of Auxora™ (zegocractin injectable emulsion) in asparaginase-induced pancreatic toxicity (AIPT).